COVID-19 in familial Mediterranean fever: Clinical course and complications related to primary disease
Avanoglu Guler et al.,
COVID-19 in familial Mediterranean fever: Clinical course and complications related to primary disease,
Modern Rheumatology, doi:10.1093/mr/roac074
Retrospective 73 familial Mediterranean fever patients with COVID-19 in Turkey, showing significantly higher risk of hospitalization for respiratory support with non-adherence to colchicine treatment before the infection.
risk of oxygen therapy, 78.8% lower, RR 0.21, p = 0.04, treatment 6 of 66 (9.1%), control 3 of 7 (42.9%), NNT 3.0, inverted to make RR<1 favor treatment, odds ratio converted to relative risk.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Avanoglu Guler et al., 21 Jul 2022, retrospective, Turkey, peer-reviewed, median age 39.5, 14 authors.
Contact:
aslihanavanoglu@gmail.com.
Abstract: Modern Rheumatology, 00, 2022, 1–6
DOI: https://doi.org/10.1093/mr/roac074
Advance Access Publication Date: 21 July 2022
Original Article
COVID-19 in familial Mediterranean fever: Clinical course
and complications related to primary disease
a
Faculty of Medicine Hospital, Department of Rheumatology, Gazi University, Ankara, Turkey
Faculty of Medicine Hospital, Department of Rheumatology, Dokuz Eylul University, Izmir, Turkey
c
Faculty of Medicine Hospital, Department of Rheumatology, Eskisehir Osmangazi University, Eskisehir, Turkey
d
Faculty of Medicine Hospital, Department of Internal Medicine, Gazi University, Ankara, Tukey
b
*Correspondence: Aslıhan Avanoglu Guler; aslihanavanoglu@gmail.com; Gazi University, Department of Internal Medicine & Rheumatology, Gazi Universitesi
Hastaneleri, Emniyet Mahallesi, Mevlana Bulvarı, Yenimahalle/Ankara 06560, Turkey.
ABSTRACT
Objectives: To evaluate the impact of familial Mediterranean fever (FMF) features on the clinical course and outcomes of coronavirus disease
2019 (COVID-19) and clinical course of FMF after COVID-19.
Methods: Consecutive FMF patients with COVID-19 were enrolled from three referral hospitals. Clinical features of FMF and detailed COVID-19
information were obtained from patient interviews and medical records.
Results: Seventy-three FMF patients were included in the study. 94.5% of patients had clinical symptoms of COVID-19. We found 24.7%
hospitalization, 12.3% respiratory support, 4.1% intensive care unit admission, 6.8% complication, and 1.4% mortality rate in patients. The
risk factors of hospitalization for respiratory support were male gender [OR: 7.167 (95% CI: 1.368–37.535)], greater age [OR: 1.067 (95% CI:
1.016–1.121)], and non-adherence to colchicine treatment before the infection [OR: 7.5 (95% CI: 1.348–41.722)]. One-third of patients had reported
attacks after COVID-19. The patterns of triggered attacks were fever, peritonitis, pleuritis, transient arthritis, chronic knee mono-arthritis, and
protracted febrile myalgia.
Conclusions: FMF characteristics were not associated with worse outcomes of COVID-19. Colchicine non-adherence was the risk factor of
hospitalization for oxygen support. The rate of FMF attacks after COVID-19 is prominently increased, with some of them being protracted and
destructive.
KEYWORDS: Coronovirus-19 disease; familial Mediterranean fever; clinical course; complication; outcome
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit